Literature DB >> 1854781

Large liposomes containing ganglioside GM1 accumulate effectively in spleen.

D Liu1, A Mori, L Huang.   

Abstract

Large liposomes, with a composition of egg phosphatidylcholine, cholesterol and ganglioside GM1, prepared by an extrusion method, were injected intravenously into mice. After 24 h, up to 50% of injected dose was accumulated in spleen compared with about 15% in spleen for liposomes containing no GM1. The effect of GM1 on spleen accumulation of liposomes was liposome size dependent. Only relatively large liposomes (d greater than 300 nm) showed high accumulation; smaller liposomes were progressively less accumulated. The spleen accumulation increased with increasing injection dose of the liposomes. It was noted that the enhanced uptake by spleen was accompanied by a decrease in the liver uptake, but the total uptake of liposomes by liver and spleen was not dependent on the diameter of liposome or the presence of the ganglioside GM1. Autoradiographs of fixed and sectioned spleen using 125I-labeled tyraminylinulin as a content marker for the liposomes, showed that liposomes localized at the reticular meshwork of the red pulp. These results suggest that larger liposomes containing GM1 are filtered by the spleen during the circulation in blood. The smaller ones with a mean diameter of less than 100 nm are not retained by the filter. The function of GM1 is to prevent liposomes from a rapid uptake by the liver so that liposomes may circulate through the spleen and be filtered. These results, together with the observation that the liposome-entrapped proteins were degraded by the spleen, suggest the potential use of these liposomes for specific drug delivery to the spleen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854781     DOI: 10.1016/0005-2736(91)90182-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

Review 1.  Biodegradable nanoparticles for cytosolic delivery of therapeutics.

Authors:  Jaspreet K Vasir; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2007-06-26       Impact factor: 15.470

Review 2.  Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery.

Authors:  Hamidreza Montazeri Aliabadi; Mostafa Shahin; Dion R Brocks; Afsaneh Lavasanifar
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 3.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

4.  Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.

Authors:  A Adedoyin; J F Bernardo; C E Swenson; L E Bolsack; G Horwith; S DeWit; E Kelly; J Klasterksy; J P Sculier; D DeValeriola; E Anaissie; G Lopez-Berestein; A Llanos-Cuentas; A Boyle; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer.

Authors:  Stavroula Sofou; Richard Enmon; Stig Palm; Barry Kappel; Pat Zanzonico; Michael R McDevitt; David A Scheinberg; George Sgouros
Journal:  J Liposome Res       Date:  2010-01-13       Impact factor: 3.648

6.  Spleen capture of nanoparticles: influence of animal species and surface characteristics.

Authors:  M Demoy; J P Andreux; C Weingarten; B Gouritin; V Guilloux; P Couvreur
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

7.  In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.

Authors:  A Mori; S P Wu; I Han; A R Khokhar; R Perez-Soler; L Huang
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

8.  Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs.

Authors:  F Liu; D Liu
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

9.  The effect of monosialylganglioside mix modifying the PEGylated liposomal epirubicin on the accelerated blood clearance phenomenon.

Authors:  Ting Zhang; Songlei Zhou; Le Kang; Xiang Luo; Yang Liu; Yanzhi Song; Xinrong Liu; Yihui Deng
Journal:  Asian J Pharm Sci       Date:  2016-08-04       Impact factor: 6.598

10.  Theranostic immunoliposomes for osteoarthritis.

Authors:  Hongsik Cho; John M Stuart; Richard Magid; Delia C Danila; Tamra Hunsaker; Eugene Pinkhassik; Karen A Hasty
Journal:  Nanomedicine       Date:  2013-10-02       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.